Progress in active-specific immunotherapy of brain malignancies

Authors: Tjoa B.A.; Salgaller M.L.

Source: Expert Opinion on Investigational Drugs, Volume 9, Number 9, September 2000 , pp. 2093-2101(9)

Buy & download fulltext article:

Price: $99.00 plus tax (Refund Policy)

Abstract:

Despite the significant advances in neurosurgical techniques and oncology treatment regimens, the prognosis of patients with brain malignancies remains dismal. Brain tumours remain as lethal in the beginning of this new millennium as they were 30 years ago. Among the promising treatment modalities being tested are various immunotherapeutic approaches. Development of cancer vaccines, also known as active-specific immunotherapy, for malignant brain tumours is summarised in this review. Understanding the mechanisms behind vaccinations and the initiation of immune response have helped the design and improvement of the efficacy of clinical vaccines. The emergence of the antigen-presenting properties of dendritic cells brings the cancer vaccine field into a new generation. Preclinical work on the use of dendritic cell-based vaccine for malignant brain tumours are encouraging. The move from these preliminary studies to the clinic is anticipated with high hope.

Keywords: brain tumour; cancer vaccine; dendritic cell; glioblastoma; glioma; immunotherapy; T-cell

Document Type: Review article

Affiliations: 1: Northwest Biotherapeutics, Inc., 21710 23rd Drive SE, Suite 100, Bothell, WA 98021, USA. mls@nwbio.org

Publication date: 2000-09-01

More about this publication?